INDIA could soon get a lot thinner – at least in theory.
On Friday, the patent on semaglutide – the molecule behind Danish drugmaker Novo Nordisk’s blockbuster weight-loss drugs Wegovy and Ozempic – expires in the country.
This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too.
Investment bank Jefferies has called it a potential “magic-pill moment” for India, predicting the semaglutide market could eventually reach $1bn domestically with the right pricing and uptake.
Analysts expect around 50 branded semaglutide generics to enter the market within months – a familiar pattern in India’s fiercely competitive pharmaceutical industry.
When the diabetes drug sitagliptin went off patent in 2022, about 30 branded versions appeared within a month and nearly 100 within a year.
India’s pharmaceutical industry, currently worth about $60bn, is expected to double by 2030. Much of it is built on generics – a manufacturing muscle that now sets the stage for fierce competition over semaglutide.
Originally developed to treat diabetes, these drugs are now being hailed as game changers for weight loss, offering results that few previous treatments could match.
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.
—BBC
Follow our WhatsApp Channel now! https://whatsapp.com/channel/0029VbAjG7g3gvWajUAEX12Q
